Post-hoc data analysis from two placebo-controlled Phase 3 clinical trials (EASE LID and EASE LID 3) for use of amantadine (Gocovri) to treat motor complications for people with Parkinson’s disease

RCT’s (n=196) of this extended-release formulation of amantadine found statistically significant improvements in motor control for daily activities compared to placebo at week 12 (least-squares mean changes from baseline of –3.4 points for Gocovri and –1.4 for placebo).

Source:

Biospace Inc.